Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.39 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20348519 | 0.90 | LOXL2 (0.43) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL3923373 | 0.86 | BCL2 (0.44) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL24348809 | 0.86 | HTR2B (0.41) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL3913251 | 0.86 | ALDH1A1 (0.52) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL23020320 | 0.84 | MIF (0.52) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL27585477 | 0.82 | HTR2B (0.40) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL3912788 | 0.81 | LMNA (0.44) | HTR2BALDH1A1MAOBHTR2CNAE1 | |
| SCHEMBL13754947 | 0.79 | KCNH2 (0.56) | ALDH1A1SMN1; SMN2MAOBTAAR1 | |
| SCHEMBL27712674 | 0.78 | HTR2B (0.37) | CALM1HTR2BALDH1A1L3MBTL1RAB9A | |
| SCHEMBL8672787 | 0.77 | HTR2B (0.41) | CALM1HTR2BALDH1A1L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632076-A | 4,6-dibenzyl pyrimidine compounds, preparing method thereof and medical uses of the compounds | 中国药科大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106632076-A | 4,6-dibenzyl pyrimidine compounds, preparing method thereof and medical uses of the compounds | 中国药科大学 | 2017-05-10 | — | — | CN | disclosed |
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | CALM1 3699/4885HTR2B 337/4885ALDH1A1 1457/4885 |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | CALM1 3532/4885HTR2B 398/4885ALDH1A1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.